Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | TP53 NTRK1 |
| Variant | TP53 - NTRK1 |
| Impact List | fusion |
| Protein Effect | unknown |
| Gene Variant Descriptions | TP53-NTRK1 results from the fusion of TP53 and NTRK1 (PMID: 24445538). TP53-NTRK1 has been identified in spitzoid tumors (PMID: 24445538), papillary thyroid cancer (PMID: 37236546), and a mesenchymal tumor (PMID: 41089504), but has not been biochemically characterized and therefore, the effect on protein function is unknown (PubMed, Jun 2026). |
| Associated Drug Resistance | |
| Category Variants Paths |
NTRK1 mutant NTRK1 rearrange NTRK1 fusion TP53 - NTRK1 TP53 mutant TP53 - NTRK1 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| TP53 - NTRK1 | infant-type hemispheric glioma | predicted - sensitive | Larotrectinib | Case Reports/Case Series | Actionable | In a clinical case study, Vitrakvi (larotrectinib) treatment resulted in an overall 65.8% size decrease in the enhancing lesions in a pediatric patient with infant-type hemispheric glioma harboring TP53-NTRK1 (PMID: 37666486). | 37666486 |